vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ECARX Holdings Inc. (ECX). Click either name above to swap in a different company.
ECARX Holdings Inc. is the larger business by last-quarter revenue ($323.3M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -21.4%, a 117.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 6.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ECARX Holdings Inc. is a global mobility technology provider specializing in integrated smart vehicle solutions, including in-vehicle infotainment systems, advanced driver assistance technologies, and connected car cloud services. It primarily partners with automotive manufacturers across the world, with a strong operational presence in the Chinese and European markets.
ACAD vs ECX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $323.3M |
| Net Profit | $273.6M | $-69.1M |
| Gross Margin | 90.8% | 15.5% |
| Operating Margin | 6.1% | -20.2% |
| Net Margin | 96.3% | -21.4% |
| Revenue YoY | 9.4% | 6.5% |
| Net Profit YoY | 90.3% | 12.8% |
| EPS (diluted) | $1.61 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | — | ||
| Q3 25 | $278.6M | — | ||
| Q2 25 | $264.6M | $323.3M | ||
| Q1 25 | $244.3M | — | ||
| Q4 24 | $259.6M | — | ||
| Q3 24 | $250.4M | — | ||
| Q2 24 | $242.0M | $303.5M | ||
| Q1 24 | $205.8M | — |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $26.7M | $-69.1M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $33.4M | $-79.2M | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | 15.5% | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | 22.6% | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | 12.2% | -20.2% | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | -22.2% | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | — | ||
| Q2 25 | 10.1% | -21.4% | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | — | ||
| Q2 24 | 13.8% | -26.1% | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | $-0.20 | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | $-0.23 | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $86.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $-293.7M |
| Total Assets | $1.6B | $494.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | $86.2M | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | $108.4M | ||
| Q1 24 | $204.7M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $917.3M | — | ||
| Q2 25 | $822.4M | $-293.7M | ||
| Q1 25 | $765.2M | — | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | — | ||
| Q2 24 | $516.7M | $-198.5M | ||
| Q1 24 | $464.0M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | $494.9M | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | — | ||
| Q2 24 | $914.1M | $555.0M | ||
| Q1 24 | $855.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-82.0M |
| Free Cash FlowOCF − Capex | — | $-86.5M |
| FCF MarginFCF / Revenue | — | -26.7% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | — | ||
| Q2 25 | $64.0M | $-82.0M | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | $25.0M | $-57.1M | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | $-86.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | $-64.9M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | -26.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | -21.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | 1.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ECX
Segment breakdown not available.
